Reactive Arthritis News

Fatigue in patients with inflammatory rheumatic and musculoskeletal diseases should be addressed with tailored physical activity, psychoeducational interventions or possibly immunomodulatory treatment, according to EULAR recommendations.

Poverty and chronic inflammation together may have a “synergistic” impact leading to higher all-cause mortality, including a 127% increased heart disease mortality risk and a 196% higher risk for cancer mortality, according to data.

Patients with immune checkpoint inhibitor-associated inflammatory arthritis who receive a biologic DMARD demonstrate quicker arthritis control, but also experience faster cancer progression, vs. methotrexate, according to data.

Routine, proactive therapeutic drug monitoring for patients receiving biopharmaceuticals for rheumatic and musculoskeletal diseases is not recommended, according to new points-to-consider published by EULAR.

United Rheumatology and CreakyJoints have announced a partnership to launch the Rheumatoid Arthritis Wellness Center, a digital resource that aims to offer support to patients living with RA, according to a press release.

Joint replacement in patients with inflammatory arthritis is often beset with pitfalls like disease flares and infectious complications, and up until recently, the emergence new treatments were rendering the current guidelines outdated.

March is Autoimmune Awareness Month, and rheumatology organizations have been using their reach and influence on social media sites to spread the word and help patients with autoimmune diseases find community.

Patients with rheumatoid arthritis who received tofacitinib demonstrated a greater risk for major adverse cardiovascular events and cancer than those treated with TNF inhibitors, according to data in The New England Journal of Medicine.

Tenosynovitis detected through power Doppler ultrasound predicts rheumatoid and inflammatory arthritis development in patients with clinically suspect arthralgia, according to data published in Arthritis Research & Therapy.